Meeting
2022 ASCO Gastrointestinal Cancers Symposium
NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US).
Authors
Arvind Dasari
University of Texas MD Anderson Cancer Center, Houston, TX
Arvind Dasari , Yan Lin , Scott Kopetz , Samuel A. Jacobs , Peter C. Lucas , Ibrahim Halil Halil Sahin , Dustin A. Deming , Philip Agop Philip , Theodore S. Hong , Norman Wolmark , Greg Yothers , Thomas J. George , Christopher Hanyoung Lieu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
DOI
10.1200/JCO.2022.40.4_suppl.TPS212
Abstract #
TPS212
Poster Bd #
N4
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
NRG GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US).
First Author: Christopher Hanyoung Lieu
Poster
2024 ASCO Gastrointestinal Cancers Symposium
NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA).
First Author: Christopher Hanyoung Lieu
Poster
2022 ASCO Annual Meeting
Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.
First Author: Arvind Dasari
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Ensemble study: A multicenter, randomized, phase III trial to test the superiority of consolidation irinotecan, capecitabine and oxaliplatin vs capecitabine and oxaliplatin following short course radiotherapy as total neoadjuvant therapy in patients with locally advanced rectal cancer.
First Author: Jun Watanabe